DENVER, CO / ACCESS Newswire / November 24, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that its management will participate at NobleCon21 - Noble Capital Markets' 21st Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
Management will be presenting on Wednesday, December 3rd at 10:30 a.m. Eastern time. A high-definition video webcast of the presentation will be available the following day on the Company's website (www.aytubio.com), and as part of a complete catalog of presentations available at Noble Capital Markets' Conference website (www.nobleconference.com) and on Channelchek (www.channelchek.com), the investor portal created by Noble. The webcast will be archived on the Company's website, the NobleCon website and on Channelchek for 90 days following the event.
Management will also be conducting one-on-one meetings at the conference. Investors should contact their Noble representatives, or Robert Blum of Lytham Partners at This email address is being protected from spambots. You need JavaScript enabled to view it., to schedule one-on-one meetings.
About Aytu BioPharma
Aytu is a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients. The Company's prescription products include EXXUA™ (gepirone) extended-release tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of major depressive disorder (MDD) and treatments for attention deficit-hyperactivity disorder (ADHD). Aytu is committed to delivering the Company's medications through best-in-class patient access programs that help to enable optimal patient outcomes. For more information, please visit aytubio.com or follow us on LinkedIn.
Contacts for Investors
Ryan Selhorn, Chief Financial Officer
Aytu BioPharma, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Robert Blum
Lytham Partners
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.59 |
| Daily Change: | 0.17 6.82 |
| Daily Volume: | 287,399 |
| Market Cap: | US$26.340M |
November 13, 2025 October 28, 2025 September 24, 2025 September 23, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
